Outer retinal degenerative diseases (RDDs) and injuries leading to photoreceptor (PR) loss are prevailing causes of blindness worldwide.
David Gamm
Researcher clinicians help bridge the gap between scientific discovery and medical care – Part 2
There is no one “typical” type of researcher clinician. There are differences in training, percentage of focus on research vs clinic, and type of research done. Many also carry teaching and administrative responsibilities on top of their already demanding positions.
David Gamm, MD, PhD – Slide of the Week
Age-related macular degeneration (AMD) causes blindness due to loss of retinal pigment epithelium (RPE) and photoreceptors (PRs), which comprise the two outermost layers of the retina.
Research beyond Waisman Center: Discoveries that have spun into products
Multiple discoveries born from the minds and hard work of Waisman Center investigators have left the nest to become successful companies or products that have had a significant impact in the world through translational research.
UW researchers will trial gene editing therapy to treat blindness
Hope for Failing Eyes
Retinal cells grown from stem cells can reach out and connect with neighbors, according to a new UW study, completing a “handshake” that may show the cells are ready for trials in humans with degenerative eye disorders.
David Gamm works to bring research and medicine into a single vision
David Gamm is adept at keeping multiple things in focus. Gamm, MD, PhD, is a Waisman investigator, director of the McPherson Eye Research Institute, and professor of ophthalmology and visual sciences. With one eye trained on patients, he treats children in the pediatric ophthalmology clinic.
Lab-grown retinal eye cells make successful connections, open door for clinical trials to treat blindness
Retinal cells grown from stem cells can reach out and connect with neighbors, according to a new study, completing a “handshake” that may show the cells are ready for trials in humans with degenerative eye disorders.
David Gamm, MD, PhD – Slide of the Week
Interphotoreceptor matrix proteoglycan 2 (IMPG2) mutations cause a severe form of early-onset retinitis pigmentosa (RP) with macular involvement.
New funding moves David Gamm’s retinitis pigmentosa treatment research into phase two
A grant from Fighting Blindness Canada will allow Dave Gamm to further test the efficacy of an induced pluripotent stem cell (iPSC) derived treatment that aims to replace damaged photoreceptor cells and restore some measure of vision.